Drugs / EV71 vaccine
EV71 vaccine
Trials 23 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04111432 Comparator | Jul → Nov 2019 | hand, foot and mouth disease | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT03296410 Comparator | Sep 2017 → Sep 2019 | hand, foot and mouth disease | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EV71 Vaccine | “A booster dose of alum-adjuvant 160U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.” NCT01734408 ↗21“This study aims to evaluate the safety, reactogenicity and immunogenicity of EV71 vaccine” NCT02200237 ↗ “the enterovirus 71 vaccine (EV71 vaccine) administered alone or simultaneously” PMID 35746502 ↗ Jun 2022 “EV71 vaccine has good safety profile and was immunogenic.” NCT01679665 ↗ “The EV71 vaccine was manufactured by Sinovac Biotech Co.” NCT05107557 ↗ |
| Known as | enterovirus 71 (EV71) vaccine | “This study tested the hypothesis that the immunogenicity and safety of the simultaneous administration of enterovirus 71 (EV71) vaccine (dose 1) with recombinant hepatitis B...” PMID 30891604 ↗ Jul 2019 |
| Known as | enterovirus 71 vaccine | “The aim of this study was to investigate the immunogenicity and safety of the enterovirus 71 vaccine (EV71 vaccine) administered alone or simultaneously.” PMID 35746502 ↗ Jun 2022 |
| Known as | EV71 vaccine (Vero cell) | “A Randomized and Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated Co-administrated With EV71 Vaccine...” NCT05107557 ↗ |
| Known as | EV71vac | “a formalin-inactivated EV71 vaccine candidate (EV71vac) at 5- and 10-µg doses” PMID 24278177 ↗ Nov 2013 |
| Known as | inactivated enterovirus 71 vaccine | “BACKGROUND: Few data exist on the immunogenicity and safety of an inactivated enterovirus 71 vaccine (EV71 vaccine) coadministered with trivalent split-virion inactivated...” PMID 36569946 ↗ Dec 20221“Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months.” PMID 24108780 ↗ Oct 2013 |
| Known as | Inactivated enterovirus 71 vaccine (human diploid cell) | “Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30” NCT06146088 ↗ |
| Known as | inactivated enterovirus A71 vaccine | “Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3-6 years and 2-35 months of age- an open-label, randomized phase IIb clinical trial.” PMID 31399275 ↗ Aug 2019 |
| Known as | Inactivated Enterovirus Type 71 Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01273246 ↗ |
| Known as | inactivated EV71 vaccine | “the inactivated EV71 vaccine (vero cell) had a clinically acceptable safety and good immunogenicity for healthy Chinese infants” NCT01636245 ↗ |
| Known as | inactivated whole EV-A71 virus vaccine | “The immunogenicity and safety of an inactivated whole EV-A71 virus vaccine were assessed in children 2 months to 6 years of age.” PMID 31399275 ↗ Aug 2019 |
| Known as | KMB-17 | “infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month).” NCT03296410 ↗ |
| Modality | Vaccine | “an inactivated alum-adjuvanted EV71 whole-virus vaccine” PMID 23541623 ↗ Mar 2013 |
| Route | Intramuscular | “Adults received intramuscular injection on Days 0, 14 and 28.” PMID 22426327 ↗ Mar 2012 |